Leo J. Hofland

Leo J. Hofland's AcademicInfluence.com Rankings

Leo J. Hofland

Philosophy

#9474

World Rank

#13039

Historical Rank

Logic

#6447

World Rank

#7964

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Leo J. Hofland's Degrees

PhD Medicine Erasmus University Rotterdam
Doctorate Medicine Erasmus University Rotterdam

Why Is Leo J. Hofland Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Leo J. Hofland's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients (1993) (1120)
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. (2008) (618)
The pathophysiological consequences of somatostatin receptor internalization and resistance. (2003) (448)
[111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. (1991) (329)
Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. (2005) (299)
The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. (2009) (292)
Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. (2004) (257)
Dopamine receptor expression and function in corticotroph pituitary tumors. (2004) (256)
The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. (2005) (252)
Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. (2010) (241)
Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. (1998) (215)
Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. (2003) (202)
Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. (1990) (197)
The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. (2004) (183)
Ghrelin secretion is inhibited by either somatostatin or cortistatin in humans. (2002) (166)
Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells. (2003) (166)
A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. (2004) (154)
Ghrelin drives GH secretion during fasting in man. (2002) (151)
Novel insights in dopamine receptor physiology. (2007) (149)
Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. (2005) (145)
Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. (1999) (135)
Somatostatin and somatostatin receptors in the immune system: a review. (2000) (130)
Autologous peripheral retinal pigment epithelium translocation in patients with subfoveal neovascular membranes (2003) (128)
The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state (2004) (126)
Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. (2013) (125)
Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment (2013) (122)
Systemic ghrelin levels in subjects with growth hormone deficiency are not modified by one year of growth hormone replacement therapy. (2001) (121)
Neuroendocrine Tumor Markers (2001) (117)
Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. (2009) (116)
Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. (2008) (115)
Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and molecular analysis. (2014) (114)
Acetylcholine regulates ghrelin secretion in humans. (2004) (114)
Pre‐clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor‐targeted scintigraphy and radionuclide therapy (1998) (109)
Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. (2008) (102)
In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells. (1999) (101)
New somatostatin analogs: will they fulfil old promises? (2002) (100)
Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. (2014) (99)
Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide. (1995) (95)
The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. (2012) (89)
Luteinizing hormone (LH)-responsive Cushing's syndrome: the demonstration of LH receptor messenger ribonucleic acid in hyperplastic adrenal cells, which respond to chorionic gonadotropin and serotonin agonists in vitro. (2003) (88)
Somatostatin and dopamine receptors as targets for medical treatment of Cushing’s Syndrome (2009) (88)
Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. (1995) (87)
Medical Treatment of Cushing’s Syndrome: Adrenal-Blocking Drugs and Ketaconazole (2010) (86)
Cortistatin rather than somatostatin as a potential endogenous ligand for somatostatin receptors in the human immune system. (2003) (86)
Immunohistochemical localization of somatostatin receptor sst2A in sarcoid granulomas (1999) (85)
Evaluation of radiolabelled bombesin analogues for receptor‐targeted scintigraphy and radiotherapy (1999) (85)
Unacylated ghrelin is active on the INS-1E rat insulinoma cell line independently of the growth hormone secretagogue receptor type 1a and the corticotropin releasing factor 2 receptor (2006) (84)
Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. (2005) (84)
The role of somatostatin and dopamine D2 receptors in endocrine tumors. (2011) (81)
Somatostatin receptor subtype expression in human tumors. (2001) (81)
Medical treatment of Cushing's disease. (2013) (81)
Low circulating IGF-I bioactivity is associated with human longevity: Findings in centenarians’ offspring (2012) (80)
Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. (2004) (79)
Type I Interferons in the Treatment of Pancreatic Cancer: Mechanisms of Action and Role of Related Receptors (2007) (76)
Somatostatin receptors in pituitary function, diagnosis and therapy. (2004) (76)
Whole-exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1. (2015) (76)
ROLE of IGF-1 System in the Modulation of Longevity: Controversies and New Insights From a Centenarians' Perspective (2019) (75)
Chromosomal instability predicts metastatic disease in patients with insulinomas. (2005) (74)
The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells. (2012) (73)
Studies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cells. (1989) (73)
Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs. (2003) (72)
Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions. (2007) (72)
Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes. (2002) (71)
Differential expression of somatostatin receptor subtypes in human peripheral blood mononuclear cell subsets. (2004) (71)
Advances in the medical treatment of Cushing's syndrome. (2019) (71)
Dopamine receptor expression and function in corticotroph ectopic tumors. (2007) (70)
Normal values of circulating insulin-like growth factor-I bioactivity in the healthy population: comparison with five widely used IGF-I immunoassays. (2008) (70)
Pre‐clinical evaluation of [111In‐DTPA‐Pro1, Tyr4]bombesin, a new radioligand for bombesin‐receptor scintigraphy (1999) (69)
Distribution pattern of somatostatin and cortistatin mRNA in human central and peripheral tissues (2004) (68)
Effect of inflammatory cytokines and growth factors on tumour cell adhesion to the peritoneum (2001) (67)
Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro. (2008) (67)
Influence of proinflammatory cytokines on the adhesion of human colon carcinoma cells to lung microvascular endothelium (2004) (66)
IFN-β Is a Highly Potent Inhibitor of Gastroenteropancreatic Neuroendocrine Tumor Cell Growth In vitro (2006) (66)
Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors (2016) (64)
Somatostatin and somatostatin receptors in retinal diseases. (2000) (64)
Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance. (2001) (63)
Pituitary tumours: The sst/D2 receptors as molecular targets (2010) (61)
Dissociation of antiproliferative and antihormonal effects of the somatostatin analog octreotide on 7315b pituitary tumor cells. (1992) (61)
Percoll density gradient centrifugation of rat pituitary tumor cells: a study of functional heterogeneity within and between tumors with respect to growth rates, prolactin production and responsiveness to the somatostatin analog SMS 201-995. (1990) (61)
The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients (2005) (60)
Neuropeptides and their receptors in the immune system. (1999) (59)
Future directions in the diagnosis and medical treatment of adrenocortical carcinoma. (2016) (58)
Somatostatin analogs in the diagnosis and treatment of cancer (2002) (58)
Somatostatin receptors and disease: role of receptor subtypes. (1996) (58)
Circulating IgGs may modulate IGF-I receptor stimulating activity in a subset of patients with Graves' ophthalmopathy. (2013) (56)
Associations between promoter usage and alternative splicing of the glucocorticoid receptor gene. (2007) (55)
Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro. (2000) (54)
β-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly. (2013) (53)
Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells. (1994) (53)
Somatostatin and somatostatin receptors in Cushing's disease (2008) (53)
Somatostatin receptor subtypes in human immune cells. (2000) (51)
The effects of bromocriptine, thyrotropin-releasing hormone, and gonadotropin-releasing hormone on hormone secretion by gonadotropin-secreting pituitary adenomas in vivo and in vitro. (1987) (51)
Somatostatin analogs: clinical application in relation to human somatostatin receptor subtypes. (1995) (50)
The role of neutrophils and oxygen free radicals in post-operative adhesions. (2006) (50)
Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. (2009) (49)
Role of tumor‐derived fibroblasts in the growth of primary cultures of human breast‐cancer cells: Effects of epidermal growth factor and the somatostatin analogue octreotide (1995) (49)
Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells (2014) (49)
Internalization of [DOTA degrees,125I-Tyr3]Octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radio-guided surgery. (1999) (48)
Somatostatin receptor subtype expression in cells of the rat immune system during adjuvant arthritis. (1999) (48)
Immunohistochemical localization of somatostatin receptor sst2A in human rheumatoid synovium. (1999) (48)
Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion. (2012) (48)
Balance between somatostatin and D2 receptor expression drives TSH‐secreting adenoma response to somatostatin analogues and dopastatins (2012) (48)
Medical Therapy of Acromegaly (2009) (48)
The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells. (2012) (47)
Effects of acute administration of acylated and unacylated ghrelin on glucose and insulin concentrations in morbidly obese subjects without overt diabetes. (2009) (47)
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study (2012) (47)
GIP‐dependent adrenal Cushing's syndrome with incomplete suppression of ACTH (2000) (46)
IGF-I Bioactivity in an Elderly Population (2010) (45)
Somatostatin receptor distribution and function in immune system. (2004) (45)
Somatostatin and somatostatin receptors: from basic concepts to clinical applications. (2010) (45)
The Expression of Adhesion Molecules and the Influence of Inflammatory Cytokines on the Adhesion of Human Pancreatic Carcinoma Cells to Mesothelial Monolayers (2006) (45)
Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia. (2014) (45)
Inflammatory Cytokines Stimulate the Adhesion of Colon Carcinoma Cells to Mesothelial Monolayers (2007) (44)
Influence of type-I Interferon receptor expression level on the response to type-I Interferons in human pancreatic cancer cells (2014) (44)
The Role of Somatostatin Analogs in Cushing's Disease (2004) (44)
Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth. (2006) (43)
Evaluation of Spheroid 3D Culture Methods to Study a Pancreatic Neuroendocrine Neoplasm Cell Line (2019) (43)
DNA copy number status is a powerful predictor of poor survival in endocrine pancreatic tumor patients. (2007) (43)
Ghrelin and its unacylated isoform stimulate the growth of adrenocortical tumor cells via an anti-apoptotic pathway. (2007) (43)
Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists. (2013) (43)
Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives (2018) (42)
In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas (2017) (42)
New insights on SOM230, a universal somatostatin receptor ligand. (2003) (42)
17-β-Estradiol-Dependent Regulation of Somatostatin Receptor Subtype Expression in the 7315b Prolactin Secreting Rat Pituitary Tumor in Vitro and in Vivo. (1997) (42)
Temozolomide-Induced Shrinkage of a Pituitary Carcinoma Causing Cushing's Disease — Report of a Case and Literature Review (2010) (41)
Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. (2016) (41)
New developments in the medical treatment of Cushing's syndrome. (2012) (41)
Bromocriptine increasingly suppresses the in vitro gonadotropin and alpha-subunit release from pituitary adenomas during long term culture. (1990) (41)
Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies. (2009) (41)
SOM230, A New Somatostatin Analogue, Is Highly Effective in the Therapy of Growth Hormone/Prolactin-Secreting Pituitary Adenomas (2007) (39)
Somatostatin is a selective chemoattractant for primitive (CD34(+)) hematopoietic progenitor cells. (2002) (39)
A COMPARISON BETWEEN THE EFFECTS OF SMS 201–995, BROMOCRIPTINE AND A COMBINATION OF BOTH DRUGS ON HORMONE RELEASE BY THE CULTURED PITUITARY TUMOUR CELLS OF ACROMEGALIC PATIENTS (1987) (38)
Role of the mTOR Pathway in Normal and Tumoral Adrenal Cells (2010) (37)
ACTH-independent macronodular adrenocortical hyperplasia reveals prevalent aberrant in vivo and in vitro responses to hormonal stimuli and coupling of arginine-vasopressin type 1a receptor to 11β-hydroxylase (2013) (37)
IGFBP‐3 is a poor parameter for assessment of clinical activity in acromegaly (1995) (36)
The role of cortistatin in the human immune system (2008) (36)
Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection (2014) (36)
Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls (2018) (34)
Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas (2007) (34)
The interrelationship between the effects of insulin-like growth factor I and somatostatin on growth hormone secretion by normal rat pituitary cells: the role of glucocorticoids. (1989) (34)
IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro. (2006) (34)
Cushing’s Disease in Dogs and Humans (2009) (33)
Reversal of endogenous dopamine receptor silencing in pituitary cells augments receptor-mediated apoptosis. (2011) (33)
Somatostatin receptors in the haematopoietic system. (2000) (32)
ANNIVERSARY REVIEW: Octreotide, 40 years later. (2019) (32)
Small intestinal neuroendocrine tumours and fibrosis: an entangled conundrum. (2017) (31)
Somatostatin receptors in the thymus. (1999) (31)
Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours. (2017) (31)
Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing’s disease (2013) (30)
Thyrotropin acts as a T-cell developmental factor in mice and humans. (2014) (30)
Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells. (2009) (30)
Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression (2018) (30)
Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response? (2015) (30)
Somatostatin receptors in malignant lymphomas: targets for radiotherapy? (2004) (29)
Peptide receptors in gut endocrine tumours. (1996) (29)
Functional role of somatostatin receptors in neuroendocrine and immune cells. (1999) (29)
Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers. (2019) (29)
In vitro and in vivo detection of functional somatostatin receptors in canine insulinomas. (1997) (29)
Physiological and pathophysiological role of somatostatin receptors in the human thymus. (2000) (29)
Systemic administration of oxytocin reduces basal and lipopolysaccharide-induced ghrelin levels in healthy men. (2009) (28)
Interferon-alpha-2a is a potent inhibitor of hormone secretion by cultured human pituitary adenomas. (1999) (28)
Role of Somatostatin Receptors in Normal and Tumoral Pituitary Corticotropic Cells (2010) (28)
Expression and functional analysis of dopamine receptor subtype 2 and somatostatin receptor subtypes in canine cushing's disease. (2008) (28)
Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study. (2019) (28)
Novel subtype specific and universal somatostatin analogues: clinical potential and pitfalls. (2005) (28)
Pro-inflammatory cytokines affect pancreatic carcinoma cell. Endothelial cell interactions. (2006) (27)
Desensitization and resensitization of rat pituitary tumor cells in long-term culture to the effects of the somatostatin analogue SMS 201-995 on cell growth and prolactin secretion. (1990) (27)
GLYCOPROTEIN HORMONE ALPHA‐SUBUNIT AND PROLACTIN RELEASE BY CULTURED PITUITARY ADENOMA CELLS FROM ACROMEGALIC PATIENTS: CORRELATION WITH GH RELEASE (1989) (27)
Synergistic activity of everolimus and 5‐aza‐2′‐deoxycytidine in medullary thyroid carcinoma cell lines (2017) (26)
Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors. (2013) (26)
Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells. (1986) (26)
Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro (2000) (26)
Melanocortin 2 receptor-associated protein (MRAP) and MRAP2 in human adrenocortical tissues: regulation of expression and association with ACTH responsiveness. (2012) (26)
A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide (1994) (26)
Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma. (2019) (25)
Somatostatin analogs: future directions. (1996) (25)
Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. (2005) (25)
Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas. (2016) (24)
A thyrotropin-secreting pituitary adenoma as a cause of thyrotoxic periodic paralysis (1998) (24)
Future clinical prospects in somatostatin/cortistatin/somatostatin receptor field (2008) (24)
Expression Stability of Reference Genes for Quantitative RT-PCR of Healthy and Diseased Pituitary Tissue Samples Varies Between Humans, Mice, and Dogs (2013) (24)
Age-related decrease of somatostatin receptor number in the normal human thymus. (2000) (24)
Hormonal and volumetric long term control of a growth hormone-releasing hormone-producing carcinoid tumor. (1999) (23)
Identification of Mutations in Cell-Free Circulating Tumor DNA in Adrenocortical Carcinoma: A Case Series. (2017) (23)
Treatment of ACTH-dependent Cushing ’ s syndrome : a consensus statement (2008) (23)
Selective Alkylation and Acylation of α and ε Amino Groups with PEG in a Somatostatin Analogue: Tailored Chemistry for Optimized Bioconjugates (2002) (23)
Polymorphonuclear leukocytes increase the adhesion of circulating tumor cells to microvascular endothelium. (2007) (23)
IGF-I bioactivity better reflects growth hormone deficiency than total IGF-I. (2011) (23)
Heterogeneity of growth hormone (GH) release by individual pituitary adenoma cells from acromegalic patients, as determined by the reverse hemolytic plaque assay: effects of SMS 201-995, GH-releasing hormone and thyrotropin-releasing hormone. (1989) (23)
Pre-clinical evaluation of [(111)In-DTPA-Pro(1), Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphy. (2000) (23)
Internalisation of isotope-coupled somatostatin analogues. (1996) (23)
Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant (2016) (23)
Insulin glargine is more potent in activating the human IGF-I receptor than human insulin and insulin detemir. (2010) (23)
Regulation of steroidogenesis in a primary pigmented nodular adrenocortical disease-associated adenoma leading to virilization and subclinical Cushing's syndrome. (2012) (22)
Cushing’s syndrome: an update on current pharmacotherapy and future directions (2015) (22)
Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. (2014) (22)
Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer (2020) (22)
Paracrine interactions between mesothelial and colon‐carcinoma cells in a rat model (1997) (21)
Weak estrogenic activity of phenol red in the culture medium: its role in the study of the regulation of prolactin release in vitro (1987) (21)
Intravenous glucose administration in fasting rats has differential effects on acylated and unacylated ghrelin in the portal and systemic circulation: a comparison between portal and peripheral concentrations in anesthetized rats. (2007) (21)
Type I interferons as radiosensitisers for pancreatic cancer. (2011) (21)
Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane. (2013) (21)
Combined treatment with PPAR-γ agonists in pancreatic cancer: a glimmer of hope for cancer therapy? (2013) (21)
Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors. (1997) (21)
IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer (2019) (21)
The role of somatostatin and somatostatin analogs in the pathophysiology of the human immune system. (2003) (20)
Future treatment strategies of aggressive pituitary tumors (2008) (20)
Somatostatin receptor manipulation. (1996) (20)
Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms. (2019) (20)
Potentials of interferon therapy in the treatment of pancreatic cancer. (2014) (20)
The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma (2016) (20)
Radioiodinated somatostatin analogue RC-160: preparation, biological activity, in vivo application in rats and comparison with [123I-Tyr3]octreotide (1993) (19)
The effect of clozapine on prolactin secretion at the level of the lactotroph. (1990) (19)
The cAMP analogs have potent anti-proliferative effects on medullary thyroid cancer cell lines (2015) (19)
The in vitro and in vivo effects of human growth hormone administration on tumor growth of rats bearing a transplantable rat pituitary tumor (7315b). (1990) (19)
Dopamine D2 receptor expression in the corticotroph cells of the human normal pituitary gland (2017) (19)
Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency. (2001) (19)
Somatostatin analogs and receptors. Diagnostic and therapeutic applications. (1997) (18)
Tissue distribution of octreotide binding receptors in normal mice and strains prone to autoimmunity (2002) (18)
Sequential ACTH and catecholamine secretion in a phaeochromocytoma. (2002) (18)
Effects of interferons α/β on the proliferation of human micro- and macrovascular endothelial cells. (2011) (17)
Tissue distribution and metabolism of radioiodinated DTPA0, D-Tyr1 and Tyr3 derivatives of octreotide in rats. (1998) (17)
Red blood cells inhibit tumour cell adhesion to the peritoneum (1999) (17)
The introduction of the IDS-iSYS total IGF-1 assay may have far-reaching consequences for diagnosis and treatment of GH deficiency. (2015) (17)
Induction of apoptosis with hybrids of Arg-Gly-Asp molecules and peptides and antimitotic effects of hybrids of cytostatic drugs and peptides. (2005) (17)
Targeting the somatostatin receptor in pituitary and neuroendocrine tumors (2013) (17)
Somatostatin receptors: clinical implications for endocrinology and oncology. (1995) (16)
Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly (2012) (16)
Long‐term in‐vitro treatment of human growth hormone (GH)‐secreting pituitary adenoma cells with octreotide causes accumulation of intracellular GH and GH mRNA levels (1992) (16)
Internalization‐defective mutants of somatostatin receptor subtype 2 exert normal signaling functions in hematopoietic cells (2001) (16)
T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly. (2020) (16)
Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives. (2015) (16)
Effects of food intake and food withholding on plasma ghrelin concentrations in healthy dogs. (2006) (16)
Somatostatin Analogues for Receptor Targeted Photodynamic Therapy (2014) (15)
The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features. (2017) (15)
Imaging and medical management of clinically nonfunctioning pituitary tumors (1995) (15)
Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors. (2019) (14)
Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas. (2007) (14)
Potential role of type I interferons in the treatment of pituitary adenomas (2009) (14)
Circulating insulin-like growth factors may contribute substantially to insulin receptor isoform A and insulin receptor isoform B signalling (2013) (14)
Studies on radiolabeled somatostatin analogues in rats and in patients. (1996) (14)
Pituitary Gland Tumors (2002) (14)
Neuroendocrine aspects of immunolymphoproliferative diseases. (2001) (14)
Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors (2013) (14)
Variations in DNA methylation of interferon gamma and programmed death 1 in allograft rejection after kidney transplantation (2016) (13)
Insulin-like growth factor I receptors on blood cells: their relationship to circulating total and "free" IGF-I, IGFBP-1, IGFBP-3 and insulin levels in healthy subjects. (1998) (13)
Differentially methylated regions in T cells identify kidney transplant patients at risk for de novo skin cancer (2018) (13)
Unsaturated fatty acids prevent desensitization of the human growth hormone secretagogue receptor by blocking its internalization. (2010) (13)
A CLOSE CORRELATION BETWEEN THE INHIBITORY EFFECTS OF INSULIN‐LIKE GROWTH FACTOR‐I AND SMS 201‐995 ON GROWTH HORMONE RELEASE BY ACROMEGALIC PITUITARY TUMOURS IN VITRO AND IN VIVO (1989) (13)
In active acromegaly, IGF1 bioactivity is related to soluble Klotho levels and quality of life (2014) (12)
Levoketoconazole, the 2S,4R Enantiomer of Ketoconazole, a New Steroidogenesis Inhibitor for Cushing's Syndrome Treatment. (2021) (12)
Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells (2016) (12)
Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene. (2016) (12)
The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures (2019) (12)
Protein kinase C-induced activin A switches adrenocortical steroidogenesis to aldosterone by suppressing CYP17A1 expression. (2013) (12)
The Influence of Reactive Oxygen Species on the Adhesion of Pancreatic Carcinoma Cells to the Peritoneum (2007) (12)
Role of the tumor microenvironment in digestive neuroendocrine tumors (2018) (11)
Effect of the Tryptophan Hydroxylase Inhibitor Telotristat on Growth and Serotonin Secretion in 2D and 3D Cultured Pancreatic Neuroendocrine Tumor Cells (2019) (11)
IGF-I bioactivity might reflect different aspects of quality of life than total IGF-I in GH-deficient patients during GH treatment. (2013) (11)
Somatostatin modulates G-CSF-induced but not interleukin-3-induced proliferative responses in myeloid 32D cells via activation of somatostatin receptor subtype 2. (2001) (11)
Effects of fasting and pegvisomant on the GH‐releasing hormone and GH‐releasing peptide‐6 stimulated growth hormone secretion (2001) (11)
In vivo and in vitro detection of dopamine d2 receptors in uveal melanomas. (2003) (11)
Somatostatin receptors in pheochromocytoma. (2004) (11)
Type I interferons in pancreatic cancer and development of new therapeutic approaches. (2020) (10)
MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer. (2019) (10)
Effects of suramin on hormone release by cultured rat anterior pituitary cells (1990) (10)
Comparison of the growth potential of retinal pigment epithelial cells obtained during vitrectomy in patients with age-related macular degeneration or complex retinal detachment (2004) (10)
There are no acute cardiac effects of a single iv dose of human ghrelin in severe growth hormone deficient patients (2004) (10)
The interrelationship between the anti‐mitotic action of the somatostatin analog octreotide and that of cytostatic drugs and suramin (1991) (10)
Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging. (2020) (10)
Somatostatin receptors: from basic science to clinical approach. Unlabeled somatostatin analogues-1: Prostate cancer. (2004) (10)
The somatostatin receptor subtype 5 in neuroendocrine tumours (2010) (10)
Octreotide, but not bromocriptine, increases circulating insulin-like growth factor binding protein 1 levels in acromegaly. (1995) (10)
The role of mTOR pathway as target for treatment in adrenocortical cancer (2019) (10)
Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumor Cells (2019) (9)
Critical appraisal of MGMT in digestive NET treated with alkylating agents. (2020) (9)
Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells (2016) (9)
Effects of acute administration of acylated and unacylated ghrelin on glucose and insulin concentrations in morbidly obese subjects without overt diabetes Short Title: Effects of AG and UAG in morbid obesity (2009) (9)
Interferon-Gamma DNA Methylation Is Affected by Mycophenolic Acid but Not by Tacrolimus after T-Cell Activation (2017) (8)
Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer (2020) (8)
Responsiveness to somatostatin analog treatment and potentials of novel somatostatin analog. (2003) (8)
Somatostatin receptor expression in thymic tumors. (2009) (8)
Surgery-derived reactive oxygen species produced by polymorphonuclear leukocytes promote tumor recurrence: studies in an in vitro model. (2007) (8)
Long-term culture of rat mammotrope and somatotrope subpopulations separated on continuous Percoll density gradients: effects of dopamine, TRH, GHRH and somatostatin. (1990) (8)
Inhibin Alpha-Subunit (INHA) Expression in Adrenocortical Cancer Is Linked to Genetic and Epigenetic INHA Promoter Variation (2014) (8)
Treatment of a thyrotropin‐secreting pituitary adenoma (TSH‐oma) with pasireotide LAR (2017) (8)
The relationship between growth hormone (GH) messenger ribonucleic acid levels and hormone release from individual cells derived from human GH‐secreting pituitary adenomas (1991) (8)
How to Differentiate Benign from Malignant Adrenocortical Tumors? (2021) (7)
Somatostatin Receptor Gene Therapy Combined With Targeted Therapy With Radiolabeled Octreotide: A New Treatment for Liver Metastases (2002) (7)
17-b-Estradiol-Dependent Regulation of Somatostatin Receptor Subtype Expression in the 7315b Prolactin Secreting Rat Pituitary Tumor in Vitro and in Vivo* (1997) (7)
Type I Interferon Receptor Expression in Human Pancreatic and Periampullary Cancer Tissue (2015) (7)
17-beta-estradiol-dependent regulation of somatostatin receptor subtype expression in the 7315b prolactin secreting rat pituitary tumor in vitro and in vivo. (1997) (7)
Leuprolide acetate therapy in LH-dependent Cushing's syndrome: in vivo and in vitro observations. (2004) (7)
Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from rat pituitary cells. (2005) (7)
Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model (2021) (6)
Selective alkylation and acylation of alpha and epsilon amino groups with PEG in a somatostatin analogue: tailored chemistry for optimized bioconjugates. (2002) (6)
Absence or low IGF‐1R‐expression in esophageal adenocarcinoma is associated with tumor invasiveness and radicality of surgical resection (2015) (6)
Sexual Dimorphism in Small-intestinal Neuroendocrine Tumors: Lower Prevalence of Mesenteric Disease in Premenopausal Women (2022) (6)
The role of somatostatin and dopamine receptors as molecular targets for the treatment of patients with pituitary adenomas. (2007) (6)
IFN-B Is a Highly Potent Inhibitor of Gastroenteropancreatic Neuroendocrine Tumor Cell Growth In vitro (2005) (5)
Interferon-a-2 a Is a Potent Inhibitor of Hormone Secretion by Cultured Human Pituitary Adenomas (1999) (5)
Changes in circulating IGF1 receptor stimulating activity do not parallel changes in total IGF1 during GH treatment of GH-deficient adults. (2015) (5)
[Acromegaly; diagnosis and treatment]. (1996) (5)
IFN-β is a potent inhibitor of insulin and insulin like growth factor stimulated proliferation and migration in human pancreatic cancer cells. (2015) (5)
Comparing the Effect of Multiple Histone Deacetylase Inhibitors on SSTR2 Expression and [111In]In-DOTATATE Uptake in NET Cells (2021) (5)
Disagreement in normative IGF‐I levels may lead to different clinical interpretations and GH dose adjustments in GH deficiency (2018) (5)
Potency of Full- Length MGF to Induce Maximal Activation of the IGF-I R Is Similar to Recombinant Human IGF-I at High Equimolar Concentrations (2016) (5)
Efficacy of a Novel Second-Generation Somatostatin-Dopamine Chimera (TBR-065) in Human Medullary Thyroid Cancer: A Preclinical Study (2020) (5)
Effects of ketoconazole on ACTH-producing and non ACTH-producing neuroendocrine tumor cells (2017) (4)
Quality of life and cortisol diurnal rhythm after 3 months of medical treatment for Cushing's disease (2011) (4)
Heterogeneity of pituitary adenoma cell subpopulations from acromegalic patients obtained by Percoll density gradient centrifugation. (1989) (4)
Does somatostatin have a role in the regulation of cortisol secretion in primary pigmented nodular adrenocortical disease (ppnad)? a clinical and in vitro investigation. (2014) (4)
Serum Insulin Bioassay Reflects Insulin Sensitivity and Requirements in Type 1 Diabetes (2017) (3)
Cabergoline treatment in Cushings disease: effect on hypertension, glucose intolerance and dyslipidemia. (2007) (3)
β-arrestin expression in corticotroph tumor cells is modulated by glucocorticoids. (2020) (3)
In active acromegaly , IGF 1 bioactivity is related to soluble Klotho levels and quality of life (2014) (3)
Recent Developments in Drug Therapy for Cushing’s Disease (2013) (3)
Translocation of autologous retinal pigment epithelium and choroid in patients with exudative age–related macular degeneration: further follow–up. (2004) (2)
A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide (2004) (2)
Expression of mTOR pathway in human adrenocortical carcinomas and in vitro effects of mTOR inhibitors in human adrenocortical cell lines (2009) (2)
Hormone and Receptor Candidates for Target and Biotherapy of Neuroendocrine Tumors. (2015) (2)
The IGF2 methylation score for adrenocortical cancer: an ENSAT validation study. (2020) (2)
The IGF pathway is activated in insulinomas but downregulated in metastatic disease. (2018) (2)
Aberrant tryptophan metabolism in stromal cells is associated with mesenteric fibrosis in small intestinal neuroendocrine tumors (2022) (2)
REGULATION OF THE EXPRESSION OF SOMATOSTATIN, CORTISTATIN AND SOMATOSTATIN RECEPTORS IN HUMAN MONOCYTES, MACROPHAGES AND DENDRITIC CELLS (2003) (2)
The Class I HDAC Inhibitor Valproic Acid Strongly Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Immune System Activation (2022) (2)
The novel somatostatin analog SOM230 has a broad spectrum of inhibitory action on hormone release by human somatotroph, corticotroph and PRL-secreting pituitary adenomas in vitro (2003) (2)
Role of Somatostatin Receptor Subtypes in Acromegaly (2005) (2)
Effect of epigenetic treatment on SST2 expression in neuroendocrine tumour patients (2022) (2)
Endocrine-Related Cancer ( 2003 ) 10 451 – 458 Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours (2004) (1)
Comparison of the in vitro effects of ketoconazole and fluconazole on human primary adrenocortical cultures and on the adrenocortical carcinoma cell line HAC15 (2010) (1)
Somatostatin and Dopamine Receptor (Co-) Expression in Neuroendocrine Tumors with Ectopic ACTH Production : Potential Targets for Medical Treatment. (2010) (1)
Peripheral glucocorticoid receptor antagonism by relacorilant with modest HPA axis disinhibition (2022) (1)
Original Article IFN-β is a potent inhibitor of insulin and insulin like growth factor stimulated proliferation and migration in human pancreatic cancer cells (2015) (1)
The effect of temozolomide on pancreatic neuroendocrine tumours and role of MGMT and MMR system in temozolomide resistance (2018) (1)
Targeting the insulin-like growth factor 1 (IGF1R) and insulin (IR) receptor with a dual IGF1R/IR inhibitor, OSI-906, to potentiate mTOR inhibitor effects in experimental models of hepatocellular carcinoma (HCC) (2014) (1)
Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study (2022) (1)
Protein kinase C-induced activin A switches adrenocortical steroidogenesis to aldosterone by suppressing CYP 17 A 1 expression (2013) (1)
Immunomodulatory antitumor effect of interferon‑beta combined with gemcitabine in pancreatic cancer. (2022) (1)
Hepatocellular carcinoma (HCC) as a neuroendocrine tumor: a preliminar molecular study. (2012) (1)
Expression of IGF/mTOR pathway components in human pheochromocytomas and in vitro inhibition of PC12 rat pheochromocytoma cell growth by mTOR inhibitors (2011) (1)
Somatostatin Control of Immune Functions (2004) (1)
Chapter 35 – Neuroendocrine Tumors (2012) (1)
Complicated Clinical Course in Incipient Gigantism Due to Treatment-resistant Aryl Hydrocarbon Receptor–Interacting Protein–mutated Pediatric Somatotropinoma (2021) (1)
MGMT expression in human adrenocortical carcinoma cell lines and tissues and effects of temozolomide on tumor cell growth. (2012) (1)
Reciprocal Interactions between Fibroblast and Pancreatic Neuroendocrine Tumor Cells: Putative Impact of the Tumor Microenvironment (2022) (1)
Lack of somatostatin analogs effectiveness in gonadotropin-secreting pituitary adenomas: Report of a case and review of the literature (2006) (1)
Direct Growth Inhibitory Action of Sandostatin on Rat Pituitary 7315b Tumor Cells in Vitro (1989) (1)
CYP11B1 variants influence skeletal maturation via alternative splicing (2021) (1)
The Effect of VPA Treatment on Radiolabeled DOTATATE Uptake: Differences Observed In Vitro and In Vivo (2022) (1)
Modifying Effects of Glucose and Insulin/Insulin-Like Growth Factors on Colon Cancer Cells (2021) (1)
Somatostatin and dopamine receptors in vitro (2004) (1)
Utility of a 3D spheroid cell culture system in neuroendocrine tumors (2018) (1)
Dopamine receptor expression and dopamine agonist effectiveness in corticotroph pituitary tumors: comparison with clinical, biochemical radiological and pathological features of patients with Cushing's disease (2008) (1)
Available 3D cultures methods: study on a Pancreatic Neuroendocrine Neoplasm cell line (2019) (1)
Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer (2022) (1)
In vitro and in vivo SST2 receptor targeted photodynamic therapy (2011) (0)
PMON148 ACQUIRED TEMOZOLOMIDE RESISTANCE IN CORTICOTROPE PITUITARY TUMOR CELLS (2022) (0)
The demethylating agent 5-aza-2-deoxycytidine upregulates somatostatin type 2 receptor expression and enhances internalization of radiolabeled somatostatin analogue in human carcinoid tumour cells (2011) (0)
T2-signal intensity, SST receptor expression and first-generation somatostatin analogs efficacy predict hormone and tumor responses to pasireotide in acromegaly (2019) (0)
Somatostatin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (0)
Macrophage-fibroblast interplay: a target for neuropeptide-based treatment of fibrotic disease? (2012) (0)
Title: The Role of Cortistatin in the Human Immune System (2008) (0)
Commentary (1995) (0)
GH receptor mRNA expression and the effect of pegvisomant on GH secretion by somatotroph pituitary adenomas (2011) (0)
The histone deacetylase inhibitor trichostatin-A reverses resistance of human adrenocortical tumour cells to apoptosis induction by type-I interferons (2006) (0)
The Somatostatin Analogue Octreotide Acts As A Vegf-c Stimulating Factor In Human Retinal Pigment Epithelium (2011) (0)
Functional heterogeneity among cell types in the normal pituitary gland and in human and rat pituitary tumors. (1989) (0)
The Expression of IGF Signaling Pathway Genes Is Frequently Elevated in Pancreatic Neuroendocrine Tumors, but Is Downregulated in Metastases (2017) (0)
Book reviews (1997) (0)
Acquired temozolomide resistance in ACTH-secreting pituitary tumour cells (2017) (0)
T2-signal intensity, SST receptor expression and first-generation somatostatin analogues efficacy predict hormone and tumor responses to pasireotide in acromegaly (2019) (0)
Subject Index Vol. 71, Suppl. 1, 2009 (2009) (0)
Comparison of 1 ! 1 In-labeled Somatostatin Analogues for Tumor Scintigraphy and Radionuclide Therapy 1 (2006) (0)
Title Page / Table of Contents / Preface (2010) (0)
Subject Index Vol. 92, 2010 (2010) (0)
Study of different in vitro systems for the evalutation of Sunitinib effects in pancreatic neuroendocrine tumour cells (2017) (0)
in the normal human thymus Age-related decrease of somatostatin receptor number (2006) (0)
Subject Index Vol. 92, 2010 (2010) (0)
Title Page / Table of Contents / Preface (2010) (0)
Role of cAMP analogs in the therapy of medullary thyroid cancer (2012) (0)
Role of IGF1 system in human longevity. A study in a wide population of centenarians and centenarians' offspring (2010) (0)
Macrophage-fibroblast interplay: a target for neuropeptide-based treatment of fibrotic disease? (2012) (0)
Response of human adrenocortical carcinoma cell lines to cytostatic drugs and mitotane and the role of the multidrug resistance pump MDR1 (2011) (0)
The ever expanding role of somatostatin receptors in endocrine disease (2007) (0)
Response of human adrenocortical carcinoma to mitotane treatment in vitro (2010) (0)
Combined effects of sirolimus and mitotane in the inhibition of growth in human adrenocortical carcinoma cells (2015) (0)
Dissecting the in vitro efficacy of octreotide and cabergoline in GH- and GH/PRL-secreting pituitary tumors. (2022) (0)
PS1-103 Pancreatic adenocarcinoma: Understanding differences in interferon pathways to optimize oncolytic virotherapy (2011) (0)
The mTOR-pathway in normal and tumoral human adrenocortical tissues (2012) (0)
Preliminary Data of Cultured Retinal Pigment Epithelial Cells Harvested from Patients With Large Neovascular Subfoveal Membranes and Other Pathology (2002) (0)
Vitro in Release by Growth Hormone- and Prolactin-Secreting Pituitary Adenomas The Novel Somatostatin Analog SOM230 Is a Potent Inhibitor of Hormone (2004) (0)
Protein Array Aqueous Humor Analysis for 120 Cytokines and Growth Factors in Uveitic Patients (2006) (0)
Implementation of SBRT as a Rescue Technique forReirradiation of Local Recurrence of Prostatic Cancer (2020) (0)
The influence of sex on the evolution of mesenteric metastasis in small intestinal neuroendocrine tumours (2019) (0)
Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls (2019) (0)
LCI699 is a potent inhibitor of cortisol production in vitro (2016) (0)
Clinical and expirimental neuroendocrinology (2008) (0)
The functional role and therapeutic potential of somatostatin receptor subtype expression in human retinal epithelium (2004) (0)
Somatostatin receptor expression in hepatocellular carcinoma: correlation between sst2 expression and patients’ survival after octreotide LAR treatment (2006) (0)
P-0045THE ROLE OF THE NOVEL SELECTIVE DUAL INHIBITOR OF THE IGF-IR/IR ON PROLIFERATION AND MIGRATION OF HUMAN PANCREATIC CANCER CELLS (2013) (0)
Pregnancy-induced Cushing[apos]s syndrome (2015) (0)
Normal Values of Circulating IGF-I Bioactivity in the Healthy Population: Comparison with five widely used IGF-I immunoassays (2008) (0)
The clinical significance of somatostatin receptor expression in human breast cancer (1995) (0)
Epigenetic interference in the interferon and gemcitabine response in pancreatic cancer (2018) (0)
Normalization of cortisol levels in Cushing's disease after medical pretreatment before surgery: effects on somatostatin receptor subtype expression and in vitro response to somatostatin analogs. (2012) (0)
Adrenal melanocortin 2 receptor associated protein (MRAP) expression is regulated by ACTH and angiotensin II, whereas MRAP2 levels are associated with ACTH responsiveness (2011) (0)
Contents Vol. 103, 2016 (2016) (0)
Acknowledgement to the Reviewers (2009) (0)
Expression Stability of Reference Genes for Quantitative RT-PCR of Healthy and Diseased Pituitary Tissue Samples Varies Between Humans, Mice, and Dogs (2013) (0)
Differential Effects of Immunosuppressive Drugs on DNA Methylation in T Cells (2017) (0)
Differentially methylated regions in T cells identify kidney transplant patients at risk for de novo skin cancer (2018) (0)
ANew Somatostatin Analogue , Is Highly Effective in the Therapy of Growth Hormone / Prolactin-Secreting PituitaryAdenomas (2007) (0)
PPAR γ activation potentiates interferon-beta activity in human pancreas adenocarcinoma through post-translational regulation of P21 and P27 (2010) (0)
Therapeutic potential of somatostatin analogues (1995) (0)
Excellent tumor response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma (2019) (0)
Potent suppression of IGF-II expression in human adrenocortical carcinoma by combined treatment with interferon-beta and DNA demethylating drugs (2008) (0)
membranes neovascular translocation in patients with subfoveal Autologous peripheral retinal pigment epithelium (2006) (0)
Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer (2020) (0)
Variations in DNA methylation of interferon gamma and programmed death 1 in allograft rejection after kidney transplantation (2016) (0)
[Prolactinoma; diagnosis and treatment]. (1996) (0)
JCEM ARCHIVEUpdate: Medical Treatment of Cushing’s Disease (2013) (0)
SAT-LB076 T2-Signal Intensity, SST Receptor Expression and First-Generation Somatostatin Analogues Efficacy Predict Hormone and Tumor Responses to Pasireotide in Acromegaly (2019) (0)
Dopamine receptor expression and dopamine agonist effectiveness in post-surgical persistent medullary thyroid cancer (2007) (0)
IGF-I response to pasireotide LAR treatment in acromegaly is mainly driven by somatostatin receptor subtype 2 expression (2018) (0)
Expression of the neuropeptide cortistatin in haematological malignancies (2007) (0)
Supplementary Material for: Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant (2016) (0)
Proteomic analysis of small intestinal neuroendocrine tumors and mesenteric fibrosis. (2023) (0)
Ghrelin/IGF-2: an autocrine regulating system of cell proliferation in neuroendocrine tumors modulated by type I interferons (2006) (0)
The Somatostatin Analog Octreotide Act as Growth Factor for Retinal Pigment Epithelium (2002) (0)
Effect of Dose and Specffic Activity on Tissue Distribution of Indium-lil-Pentetreotide in Rats (2006) (0)
Comparison of 1!1In-labeled Somatostatin Analogues for Tumor Scintigraphy and Radionuclide Therapy1 (2006) (0)
A Prospective Trial With Ketoconazole Induction Therapy and Octreotide Maintenance Treatment of Cushing’s Disease (2021) (0)
Expression of mTOR and IGF2 and in vitro effects of mTOR inhibitor drugs on cell proliferation and cortisol production in human adrenocortical cancer cells (2010) (0)
Identification of molecular targets of Sunitinib in pancreatic neuroendocrine tumours (2017) (0)

This paper list is powered by the following services:

Leo J. Hofland's Academic­Influence.com Rankings

Leo J. Hofland's Degrees

Why Is Leo J. Hofland Influential?

Leo J. Hofland's Published Works

Published Works

Leo J. Hofland's AcademicInfluence.com Rankings